Hua Fan1, Juan Du2, Xia Liu1, Wei-Wei Zheng1, Ze-Hao Zhuang1, Cheng-Dang Wang1, Rui Gao1. 1. Department of Gastroenterology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian Province, China. 2. Second Department of Gastroenterology, General Hospital of Yankuang Group, Zoucheng, Shandong Province, China.
Abstract
BACKGROUND/AIMS: The aim of the present study was to investigate the effects of the combination treatment of pentasa and probiotics on the microflora composition and prognosis in patients with inflammatory bowel disease (IBD). MATERIALS AND METHODS: A total of 40 patients with IBD (19 control group and 21 observation group) were randomized. Patients in the control group were given pentasa, and patients in the observation group were given probiotics along with pentasa. The microflora composition, biochemical indices, inflammatory markers, and activity scores of the two groups were analyzed. RESULTS: After treatment, the number of enterobacteria, enterococci, saccharomyces, and bacteroides; the levels of fecal lactoferrin, 1-antitrypsin, β2-microglobulin, high-sensitivity C-reactive protein, and interleukin (IL)-6; activity scores; and recurrence rate in the observation group were significantly lower than those in the control group. Bifidobacterium and lactobacillus counts and IL-4 levels were significantly higher in the observation group than in the control group. CONCLUSION: The combination of probiotics and pentasa can improve microflora composition in patients with IBD and reduce the level of inflammatory cytokines; therefore, it is worthy of further clinical validation.
RCT Entities:
BACKGROUND/AIMS: The aim of the present study was to investigate the effects of the combination treatment of pentasa and probiotics on the microflora composition and prognosis in patients with inflammatory bowel disease (IBD). MATERIALS AND METHODS: A total of 40 patients with IBD (19 control group and 21 observation group) were randomized. Patients in the control group were given pentasa, and patients in the observation group were given probiotics along with pentasa. The microflora composition, biochemical indices, inflammatory markers, and activity scores of the two groups were analyzed. RESULTS: After treatment, the number of enterobacteria, enterococci, saccharomyces, and bacteroides; the levels of fecal lactoferrin, 1-antitrypsin, β2-microglobulin, high-sensitivity C-reactive protein, and interleukin (IL)-6; activity scores; and recurrence rate in the observation group were significantly lower than those in the control group. Bifidobacterium and lactobacillus counts and IL-4 levels were significantly higher in the observation group than in the control group. CONCLUSION: The combination of probiotics and pentasa can improve microflora composition in patients with IBD and reduce the level of inflammatory cytokines; therefore, it is worthy of further clinical validation.
Authors: S John Curnow; Dagmar Scheel-Toellner; Will Jenkinson; Karim Raza; Omar M Durrani; Jeff M Faint; Saaeha Rauz; Kaska Wloka; Darrell Pilling; Stefan Rose-John; Christopher D Buckley; Philip I Murray; Mike Salmon Journal: J Immunol Date: 2004-10-15 Impact factor: 5.422
Authors: Puja Vora Khanna; David Quan Shih; Talin Haritunians; Dermot Patrick McGovern; Stephan Targan Journal: Semin Immunopathol Date: 2014-09-12 Impact factor: 9.623
Authors: Viktoria V Мokrozub; Liudmyla M Lazarenko; Liubov M Sichel; Lidia P Babenko; Petro M Lytvyn; Olga M Demchenko; Yulia O Melnichenko; Nadiya V Boyko; Bruno Biavati; Diana DiGioia; Rostyslav V Bubnov; Mykola Ya Spivak Journal: EPMA J Date: 2015-06-19 Impact factor: 6.543
Authors: Renata Curciarello; Karina E Canziani; Ileana Salto; Emanuel Barbiera Romero; Andrés Rocca; Ivan Doldan; Emmanuel Peton; Santiago Brayer; Alicia M Sambuelli; Silvina Goncalves; Pablo Tirado; Gustavo J Correa; Martín Yantorno; Laura Garbi; Guillermo H Docena; María de Los Ángeles Serradell; Cecilia I Muglia Journal: Front Pharmacol Date: 2021-04-15 Impact factor: 5.810